Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR)

Price$12.54

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-30.32%

Price vs S&P 500 (4W)1.05%

VGM Score44.72

Market Capitalization$765.58M

P/E Ratio (Annual)309.55x

All Metrics

P/CF (Annual)16.13x

Book Value / Share (Quarterly)$0.38

P/TBV (Annual)7.77x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)22.30%

Cash Flow / Share (Quarterly)$0.08

Price vs S&P 500 (YTD)-28.99%

Gross Margin (TTM)88.15%

Net Profit Margin (TTM)3.34%

EPS (TTM)$0.02

10-Day Avg Trading Volume12.71M

EPS Excl Extra (TTM)$0.02

Revenue Growth (5Y)12.13%

EPS (Annual)$0.00

ROI (Annual)0.73%

Gross Margin (Annual)87.90%

Net Profit Margin (5Y Avg)1.43%

Cash / Share (Quarterly)$0.24

P/E Basic Excl Extra (TTM)71.39x

Revenue Growth QoQ (YoY)-8.40%

EPS Growth (5Y)-41.47%

P/E Normalized (Annual)309.55x

ROA (Last FY)0.57%

Revenue Growth TTM (YoY)15.20%

EBITD / Share (TTM)$0.06

ROE (5Y Avg)1.16%

Operating Margin (TTM)7.57%

Cash Flow / Share (Annual)$0.08

P/B Ratio3.28x

P/B Ratio (Quarterly)4.31x

Net Income / Employee (Annual)$7,000

EV / Revenue (TTM)2.56x

Net Interest Coverage (TTM)1.99x

ROA (TTM)2.59%

EPS Growth QoQ (YoY)80.95%

EV / EBITDA (TTM)23.81x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)2.59x

Quick Ratio (Quarterly)2.06x

3-Month Avg Trading Volume12.46M

52-Week Price Return10.21%

EV / Free Cash Flow (Annual)17.53x

P/E Incl Extra (TTM)71.39x

Revenue / Employee (TTM)$907,800

Tangible BV / Share (Quarterly)$0.20

P/S Ratio (Annual)2.35x

Asset Turnover (Annual)0.75x

52-Week High$1.82

Operating Margin (5Y Avg)3.49%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-45.22%

Tangible BV CAGR (5Y)10.15%

26-Week Price Return-22.40%

Quick Ratio (Annual)1.97x

13-Week Price Return-18.79%

Total Debt / Equity (Annual)0.42x

Current Ratio (Quarterly)2.63x

Enterprise Value$946.03M

Revenue / Share Growth (5Y)10.13%

Asset Turnover (TTM)0.77x

Book Value / Share Growth (5Y)6.58%

Revenue / Employee (Annual)$924,200

Inventory Turnover (Annual)0.75x

Pretax Margin (Annual)3.42%

Cash / Share (Annual)$0.26

3-Month Return Std Dev61.59%

Gross Margin (5Y Avg)89.31%

Net Income / Employee (TTM)$30,400

EBITDA CAGR (5Y)-15.39%

EBITDA Interim CAGR (5Y)-34.72%

ROE (Last FY)1.03%

Net Interest Coverage (Annual)1.99x

EPS Basic Excl Extra (Annual)$0.00

P/FCF (TTM)15.83x

Receivables Turnover (TTM)6.87x

EV / Free Cash Flow (TTM)16.98x

Total Debt / Equity (Quarterly)0.43x

EPS Incl Extra (TTM)$0.02

Receivables Turnover (Annual)9.03x

ROI (TTM)3.21%

P/S Ratio (TTM)2.39x

Pretax Margin (5Y Avg)2.91%

Revenue / Share (Annual)$0.50

Tangible BV / Share (Annual)$0.21

Forward P/E38.36x

Free OCF CAGR (5Y)-4.61%

Price vs S&P 500 (52W)-14.16%

P/E Ratio (TTM)71.39x

Year-to-Date Return-21.63%

5-Day Price Return-0.53%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)0.51%

Net Profit Margin (Annual)0.76%

Month-to-Date Return-2.95%

Cash Flow / Share (TTM)$-0.01

EBITD / Share (Annual)$0.05

EPS Growth (3Y)-41.82%

Operating Margin (Annual)6.87%

LT Debt / Equity (Annual)0.33x

P/CF (TTM)15.63x

ROI (5Y Avg)0.53%

P/E Excl Extra (TTM)71.39x

LT Debt / Equity (Quarterly)0.35x

EPS Basic Excl Extra (TTM)$0.02

P/TBV (Quarterly)8.40x

P/B Ratio (Annual)4.06x

Inventory Turnover (TTM)0.71x

Pretax Margin (TTM)5.38%

Book Value / Share (Annual)$0.39

Price vs S&P 500 (13W)-27.04%

Net Margin Growth (5Y)-46.77%

Beta0.46x

P/FCF (Annual)16.35x

Revenue / Share (TTM)$0.50

ROE (TTM)4.71%

52-Week Low$0.84

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.43

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PHARPharming Group N.V. ADS, each representing 10 ordinary shares	C	C	C	$12.54
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Pharming Group is a biopharmaceutical company focused on rare and life-threatening diseases with unmet medical needs. It markets RUCONEST for hereditary angioedema (HAE) and Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, supported by a pipeline of biologic and small-molecule therapies in development.